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The following extended abstracts were presented at the Research Initiatives 
in Vascular Disease Conference, The Biology of Vascular Interventions-- 
Minimally Invasive Approaches to Vascular Disease, sponsored by The Lifeline 
Foundation and the Cardiovascular & Interventional Radiology Research and 
Educational Foundation; jointly sponsored by th  International Society for 
Cardiovascular Surgery, North American Chapter, The Society for Vascular 
Surgery, and The Society of Cardiovascular and Interventional Radiology; in 
cooperation with the National Institutes of Health-National Heart, Lung, & 
Blood Institute on Feb 17-18, 2000 in Bethesda, Md. 
HORIZONS OF ATHEROSCLEROSIS 
RESEARCH AND THERAPY 
Peter Libby 
Brigham and Women's Hospital and Harvard Medical School 
Boston, Mass 
The treatment of coronary artery disease has wit- 
nessed a revolution i  the last quarter century. We have 
mastered the diagnosis of coronary stenoses and car- 
diac ischemia. We have t hand an array of extremely 
effective therapies for treating ischemia, including 
medical therapy, and percutaneous and surgical revas- 
cularization. Yet, these modalities do not prolong life 
or prevent myocardial infarction except in selected 
subgroups. With regard to coronary risk reduction, we 
have also made considerable progress. Data from mul- 
tiple clinical trials with LDL lowering agents have fially 
vindicated the "cholesterol hypothesis," documenting 
a reduction in coronary events and reducing all-cause 
mortality. Yet, even the most effective current hera- 
pies fail to prevent the majority of coronary events, and 
most patients with atherosclerosis have LDL levels in 
the "average" range. Thus, much remains to be done 
to combat he residual burden of atherosclerotic dis- 
ease. In preparation for this task, we need to take into 
account shifting demographics and the merging ther: 
apeutic targets. We will witness manifold emograph- 
ic changes in coronary disease the next 20 years. The 
most important will be Globalization, Aging, and 
increasing adiposity and hence, the insulin resistance 
syndrome. New therapeutic opporttmities will include 
aspects ofdysllpidemias beyond LDL, including strate~ 
gies to manipulate HDL (eg, Apo A-l, CETP, SRB-1, 
ABC-1), and "diabetic dyslipidemia" (PPAR-alpha 
agonists and insulin sensitizers including the PPAR- 
gamma gonists). Novel lipid-directed therapeutic tar- 
gets also include cholesterol absorption and ACAT 
inhibitors. Aside from strategies targeting lipids, we 
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will need to seek more information about nontradi- 
tional risk factors and their treatment, including 
antioxidants, Lp(a), homocysteine, and infectious 
agents. Although we can look back with some satisfac- 
tion on the advances of recent years in treatment of 
atherosclerosis, wemust not become complacent, but 
pursue new avenues to limit even further the world- 
wide spread of this major cause of illness and death. 
VEGF- INDUCTION OF ANGIOGENESIS 
Jeffrey M. Isner, MD 
St Elizabeths Medical Center 
Boston, Mass 
The therapeutic implications of angiogenic growth 
factors were identified by the pioneering work of 
Folkman and colleagues over two decades ago. 1 Their 
work documented the extent o which tumor devel- 
opment was dependent upon neovascularization a d 
suggested that this relationship might involve angio- 
genic growth factors that were specific for neoplasms. 
Subsequent i vestigations have established the f asibil- 
ity of using recombinant formulations of such angio- 
genic growth factors to expedite and/or augment col- 
lateral artery development in animal models of 
• myocardial nd hindlimb ischemia. This novel strategy 
for the treatment ofvascular insufficiency was termed 
therapeutic angiogenesis. 2 More recent data suggest 
that the basis for native as well as therapeutic neovas- 
cularization is not restricted to angiogenesis, but 
includes postnatal vasculogenesis a well. Data sup- 
porting these notions as well as derivative concepts and 
concerns are the subject of this Perspective. 
Therapeutic angiogenesis 
Preclinical studies established that angiogenic 
growth factors could promote collateral artery 
development in animal models of peripheral and 
myocardial ischemia (reviewed in 3). Morphometric 
analyses documented that such enhanced vascularity 
encompassed a range of vessel caliber, from medi- 
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